Susquehanna International Group
CRNX icon

Susquehanna International Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Susquehanna International Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.68M Buy
46,253
+12,742
+38% +$569K ﹤0.01% 6575
2025
Q4 		$1.56M Sell
33,511
-223,994
-87% -$9.97M ﹤0.01% 6155
2025
Q3 		$10.7M Buy
257,505
+129,841
+102% +$4.15M ﹤0.01% 2952
2025
Q2 		$3.67M Sell
127,664
-10,371
-8% -$320K ﹤0.01% 4560
2025
Q1 		$4.63M Buy
138,035
+87,784
+175% +$3.28M ﹤0.01% 3790
2024
Q4 		$2.57M Buy
50,251
+436
+0.9% +$24.4K ﹤0.01% 4763
2024
Q3 		$2.55M Buy
49,815
+13,955
+39% +$720K ﹤0.01% 4826
2024
Q2 		$1.61M Sell
35,860
-14,422
-29% -$666K ﹤0.01% 5522
2024
Q1 		$2.35M Buy
50,282
+26,600
+112% +$1.04M ﹤0.01% 4977
2023
Q4 		$843K Sell
23,682
-51,461
-68% -$1.58M ﹤0.01% 7399
2023
Q3 		$2.23M Buy
75,143
+47,716
+174% +$983K ﹤0.01% 4910
2023
Q2 		$494K Sell
27,427
-34,560
-56% -$689K ﹤0.01% 8345
2023
Q1 		$996K Buy
61,987
+51,752
+506% +$958K ﹤0.01% 6831
2022
Q4 		$187K Sell
10,235
-26,062
-72% -$459K ﹤0.01% 10229
2022
Q3 		$713K Buy
36,297
+23,628
+187% +$482K ﹤0.01% 7514
2022
Q2 		$236K Sell
12,669
-65,238
-84% -$1.3M ﹤0.01% 10209
2022
Q1 		$1.71M Buy
77,907
+30,991
+66% +$627K ﹤0.01% 5826
2021
Q4 		$1.33M Buy
46,916
+31,869
+212% +$786K ﹤0.01% 6505
2021
Q3 		$317K Buy
+15,047
New +$315K ﹤0.01% 10479

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Susquehanna International Group's CRNX Position: Q1 2026 in Review

Susquehanna International Group increased its Crinetics Pharmaceuticals (CRNX) stake by 38% in Q1 2026, buying an estimated $569K and bringing the position to 46,253 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #6575.

Susquehanna International Group first reported a position in CRNX in Q3 2021 and has held it in 19 quarters since. The position peaked at $10.7M in Q3 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Susquehanna International Group held 46,253 shares of Crinetics Pharmaceuticals worth $1.68M as of Q1 2026.
  • Susquehanna International Group bought 12,742 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $569K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6575 holding.
  • Susquehanna International Group first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Susquehanna International Group's Crinetics Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.